GLAUKOS Corp revenue by segment GKOS

GLAUKOS Corp splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Glaucoma at $421.1 million, 83% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
690
507
383
315
283
294
225
237
181
159
114
Glaucoma
556
+43.9%
share 80.5%
421
+38.8%
share 83.0%
303
+27.9%
share 79.1%
237
+10.6%
share 75.3%
214
-7.6%
share 75.7%
232
+29.3%
share 78.9%
179
-22.3%
share 79.7%
231
+27.4%
share 97.5%
181
+13.8%
share 100.0%
159
share 100.0%
—
Corneal Health
135
+60.9%
share 19.5%
86
+7.7%
share 17.0%
80
+3.3%
share 20.9%
78
+13.2%
share 24.7%
69
+10.6%
share 24.3%
62
+36.1%
share 21.1%
46
+657.8%
share 20.3%
6
share 2.5%
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
GKOS (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Aliso Viejo, CA
SEC filer status
Large accelerated filer
SEC CIK
1192448

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.